A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Recruiting now

Conditions studied: Gastric Cancer, RWS, PD-1 Immunotherapy

In brief

The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment

Key facts

Study ID

NCT06485271

Run by

Changzhi People's Hospital Affiliated to Changzhi Medical College

People needed

504

Starts

2023-11-01

Expected to finish

2026-10-01

Last updated by the study team

2024-07-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years old, both male and female;
• patients with advanced gastric cancer diagnosed by pathology or histology and progressed or recurred after 6 months of adjuvant therapy can also be considered for enrollment;
• Have at least one measurable lesion on imaging (RECIST 1.1 criteria), the spiral CT or MR target lesion should be ≥10 mm and lymph node ≥15 mm;
• The investigator determines that the patient is amenable to treatment with karelizumab or apatinib;
• Voluntary enrollment; good compliance and willingness to cooperate with follow-up.

You may not qualify if…

• Pregnant or lactating women;
• Previous use of other immunotherapy drugs (e.g. PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA4 monoclonal antibody, etc.);
• Prior use of other anti-angiogenic therapeutic agents (e.g., apatinib, etc.);
• Patients who, in the judgment of the investigator, are not suitable for inclusion.

Where it is running

• Changzhi People's Hospital Affiliated to Changzhi Medical College — Changzhi, Shanxi, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.